Easy Branches allows you to share your guest post within our network in any countries of the world to reach Global customers start sharing your stories today!

Easy Branches

34/17 Moo 3 Chao fah west Road, Phuket, Thailand, Phuket

Call: 076 367 766

info@easybranches.com

Financial Markets

Zydus Lifes gains after receiving approval from COFEPRIS for Bevacizumab biosimilar

Zydus Lifesciences rose 1.52% to Rs 1161.95 after the Mexican regulatory authority COFEPRIS (Federal Commission for the Protection Against Sanitary Risk) granted marketing approval to the company for Bhava, a Bevacizumab biosimilar.

By: business-standard.com

Jul 22 2024
0
0 Views

Zydus Lifes gains after receiving approval from COFEPRIS for Bevacizumab biosimilar

Zydus Lifes gains after receiving approval from COFEPRIS for Bevacizumab biosimilar

Related

Nippon Life climbs as Q1 PAT surges 40% YoY to Rs 332 crore

Oberoi Realty spurts as Q1 PAT soars 82% YoY to Rs 584 crore

Union Bank of India edges higher after Q1 PAT rises nearly 14% YoY; NIM at 3.05%

HDFC Bank rises as Q1 PAT grows 35% YoY to Rs 16,175 crore

TARC appoints Abu Dhabi- based contractor for its upcoming luxury residential projects

Wipro fails to show revival signs; may underperform peers, say analysts

Indices pare losses; pharma shares advance

US Stocks Extend Downside Amid Profit Taking

RNFI Services IPO opens today: Check GMP, Dates, Price, Size and more

Volumes soar at Oberoi Realty Ltd counter

Zydus Lifes gains after receiving approval from COFEPRIS for Bevacizumab biosimilar

LIC stock is up 16% in July on the BSE; what's fueling the rise? Check here

Nippon Life climbs as Q1 PAT surges 40% YoY to Rs 332 crore